跳至主要内容
临床试验/NCT02798679
NCT02798679已完成不适用

Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

University of Minnesota1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2016年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Cardiotoxicity assessed clinically or by cardiac MRI

研究概览

简要总结

The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stage I-III breast cancer or lymphoma with a >2 year life expectancy
  • A treatment plan that includes anthracyclines and/or trastuzumab
  • Age >45 years
  • Able to hold breath for 10 seconds
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

排除标准

  • Refusal or inability to provide informed consent
  • Known heart failure or LVEF <50%
  • Heart rate over 100 bpm
  • Renal dysfunction with GFR <30 mL/min/1.73m2
  • Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
  • Symptomatic claustrophobia
  • Plans to move within 24 months of enrollment

结局指标

主要结局

Cardiotoxicity assessed clinically or by cardiac MRI

时间窗: 24 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验